De Clercq E
Rega Institute for Medical Research, Katholieke Universiteit, Leuven.
Verh K Acad Geneeskd Belg. 1996;58(1):19-47; discussion 47-9.
(S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC, Cidofovir, Vistide) is an acyclic nucleoside phosphonate with broad-spectrum activity against a wide variety of DNA viruses including herpesviruses [Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus type 6 (HHV-6) and equine and bovine herpesviruses], papovaviruses [human polyoma virus and human papilloma virus (HPV)], adeno-, irido-, hepadna-, and poxviruses. HPMPC has proved effective against these viruses in different cell culture systems and/or animal models. The mechanism of action of HPMPC is based upon the interaction of its active intracellular metabolite, the diphosphorylated HPMPC derivative HPMPCpp, with the viral DNA polymerase. HPMPCpp has been shown to block CMV DNA synthesis by DNA chain termination following incorporation of two consecutive HPMPC molecules at the 3'-end of the DNA chain. HPMPC confers a prolonged antiviral action, which lasts for several days or weeks, thus allowing infrequent dosing (i.e. every week or every two weeks). This prolonged antiviral action is probably due to the very long intracellular half-life of the HPMPC metabolites, particularly the HPMPCp-choline adduct. In clinical studies, HPMPC has proved efficacious in the treatment of CMV retinitis, following both intravenous injection (3 or 5 mg/kg, every other week) and intravitreal injection (single dose of 20 micrograms per eye). Initial clinical trials also point to the efficacy of both systemic (intravenous) and topical HPMPC (1% ointment) in the treatment of acyclovir-resistant HSV infections, and of topical HPMPC (ointment or injection) in the treatment of pharyngeal, laryngeal and anogenital HPV infections. HPMPC is now being pursued in the topical and/or systemic (intravenous) treatment of various infections due to CMV, HSV, VZV, EBV, HPV, polyoma-, adeno- and poxviruses.
(S)-1-(3-羟基-2-膦酰甲氧基丙基)胞嘧啶(HPMPC,西多福韦,Vistide)是一种无环核苷膦酸盐,对多种DNA病毒具有广谱活性,包括疱疹病毒[1型单纯疱疹病毒(HSV-1)和2型单纯疱疹病毒(HSV-2)、水痘带状疱疹病毒(VZV)、巨细胞病毒(CMV)、爱泼斯坦-巴尔病毒(EBV)、人类疱疹病毒6型(HHV-6)以及马和牛疱疹病毒];乳头多瘤空泡病毒[人类多瘤病毒和人乳头瘤病毒(HPV)];腺病毒、虹彩病毒、嗜肝DNA病毒和痘病毒。在不同的细胞培养系统和/或动物模型中,HPMPC已被证明对这些病毒有效。HPMPC的作用机制基于其活性细胞内代谢产物二磷酸化的HPMPC衍生物HPMPCpp与病毒DNA聚合酶的相互作用。已表明,HPMPCpp通过在DNA链的3'-末端掺入两个连续的HPMPC分子后导致DNA链终止来阻断CMV DNA合成。HPMPC具有持久的抗病毒作用,可持续数天或数周,因此给药频率较低(即每周或每两周一次)。这种持久的抗病毒作用可能是由于HPMPC代谢产物,特别是HPMPCp-胆碱加合物的细胞内半衰期非常长。在临床研究中,静脉注射(3或5mg/kg,每隔一周一次)和玻璃体内注射(单剂量20μg/眼)后,HPMPC已被证明对治疗CMV视网膜炎有效。最初的临床试验还表明,全身(静脉内)和局部HPMPC(1%软膏)在治疗阿昔洛韦耐药HSV感染方面有效,局部HPMPC(软膏或注射)在治疗咽部、喉部和肛门生殖器HPV感染方面有效。目前正在探索将HPMPC用于局部和/或全身(静脉内)治疗由CMV、HSV、VZV、EBV、HPV、多瘤病毒、腺病毒和痘病毒引起的各种感染。